Consensus guidelines suggest that screening for germline BAP1 mutations in mesothelioma patients who are members of families with multiple cases of mesothelioma, melanoma, renal cell carcinoma, cholangiocarcinoma, basal cell carcinoma, can lead to early detection that can be life saving for several of these malignancies, or at least to better therapeutic options when cancers are treated at an early stage [7]. This evidence concerns the gene BAP1 and hereditary clear cell renal cell carcinoma.